Given that many cancers tend to develop resistance to single-target EGFR inhibitors in clinical settings, dual inhibitors designed to simultaneously target EGFR and HER2 have been introduced to enhance therapeutic efficacy, minimize drug resistance and interactions, and promote better patient compliance [18]. This evidence concerns the gene ERBB2 and cancer.